Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its Phase III drug Aimovig reduced monthly migraine attacks in half.
Alder BioPharmaceuticals announced that its migraine drug eptinezumab succeeded in a late-stage trial for migraine – but shares immediately fell as investors raised concerns about a strong placebo effect.